Capsovision, Inc (CV) Stock Price & Analysis
Capsovision, Inc (CV) fell 1.67% to USD 6.49 as of July 26, 2026 at 09:44 UTC, according to Nexqual real-time market data.
CV last closed at USD 6.6; the session ranged USD 6.4–6.77 on volume of 65,344 shares. Market capitalization is $324.26M, with a 52-week range of USD 3.43–15.37 (NCM). Source: Nexqual, July 26, 2026 at 09:44 UTC.
Key Statistics (as of July 26, 2026 at 09:44 UTC)
| Price | USD 6.49 |
|---|---|
| Change | ▼ 1.67% (down) |
| Previous Close | USD 6.6 |
| Open | USD 6.77 |
| Day Range | USD 6.4 – 6.77 |
| 52-Week Range | USD 3.43 – 15.37 |
| Volume | 65,344 shares |
| Market Cap | $324.26M |
| Exchange | NCM |
Technical Analysis (CV)
Nexqual's technical model rates CV "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 26, 2026 at 09:44 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 45.94 (neutral) |
| vs SMA50 | Below (USD 6.78) |
| MACD | -0.05 (negative) |
Analyst Ratings (CV)
Wall Street analysts rate CV "None" based on 1 analysts, with a mean price target of USD 10 (range USD 10–10), per Nexqual as of July 26, 2026 at 09:44 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 10 |
| High Target | USD 10 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (CV)
| Next Earnings Date | 2026-08-13 |
|---|---|
| Revenue Estimate | $3.81M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.15 vs est -0.13 ▼ miss |
| 2025-12-31 | USD -0.16 vs est -0.15 ▼ miss |
| 2025-09-30 | USD -0.17 vs est -0.13 ▼ miss |
| 2025-06-30 | USD -0.1 vs est -0.11 ▲ beat |
Source: Nexqual, July 26, 2026 at 09:44 UTC.
Financials & Fundamentals (CV)
| Total Revenue | $13.56M |
|---|---|
| Revenue Growth (YoY) | +0.30% |
| Gross Margin | +51.67% |
| Operating Margin | -254.05% |
| Profit Margin | -198.87% |
| ROE | -185.09% |
| Debt / Equity | 3.9 |
| Current Ratio | 4.57 |
| Total Cash | $17.93M |
| Total Debt | $788,000 |
| Free Cash Flow | $-13.24M |
Source: Nexqual, July 26, 2026 at 09:44 UTC.
Financial Health Score (CV)
Nexqual rates Capsovision, Inc's overall financial health "Weak" across five dimensions, as of July 26, 2026 at 09:44 UTC.
| Growth | Mixed — Revenue +0.3% YoY (latest Q), slow |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $18M cash, no debt |
| Cash Flow | Weak — FCF negative: -$13M, burning cash |
| Efficiency | Critical — ROE -185%, ROA -88.1% |
Ownership (CV)
| Insider Ownership | +32.09% |
|---|---|
| Institutional Ownership | +8.15% |
| Shares Outstanding | 49.96M |
| Float | 31.41M |
| Short % of Float | +5.62% |
Source: Nexqual, July 26, 2026 at 09:44 UTC.
Leadership (CV)
Capsovision, Inc is led by Kang-Huai Wang (age 68), Co-Founder, President, CEO & Director, per Nexqual as of July 26, 2026 at 09:44 UTC.
| Co-Founder, President, CEO & Director | Kang-Huai Wang (age 68) |
|---|---|
| Senior Vice President of Global Sales | Douglas Atkinson (age 57) |
Major Backers & Investors (CV)
Notable institutional backers of Capsovision, Inc include Fidelity, UBS Group AG, Xtx Topco Ltd, according to Nexqual as of July 26, 2026 at 09:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.61% |
| UBS Group AG | 0.13% |
| Xtx Topco Ltd | 0.13% |
| Charles Schwab Investment Management, Inc. | 0.12% |
| Charles Schwab | 0.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.54% |
| BlackRock | 4.34% |
| Geode Capital | 0.87% |
| State Street | 0.51% |
| Northern Trust | 0.3% |
Source: Nexqual, July 26, 2026 at 09:44 UTC.
From Capsovision, Inc's Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Our CapsoCam Colon (subject to FDA clearance) incorporates our proprietary 3D-sensing technology to more accurately measure polyp sizes.
- For the years ended December 31, 2025 and 2024, we generated approximately $13.6 million and $11.8 million, respectively, in revenue from sales of CapsoCam Plus, an increase of approximately 15% over the prior year.
- Our CapsoCam Colon also incorporates our proprietary 3D-sensing technology to more accurately measure the size of polyps in the GI tract, enabling physicians to more confidently decide that patients with small (e.g., less than 6mm) polyps may forgo a follow-on colonoscopy, increasing the utility of the procedure for healthcare providers and patients alike.
- Building upon the commercial success and the existing design of our CapsoCam Plus capsule, we developed our next pipeline capsule endoscope, CapsoCam Colon.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CNL | Collective Mining Ltd. | USD 12.8 | ▼ 3.32% |
| EE | Excelerate Energy, Inc. | USD 38.63 | ▼ 2.33% |
| UTL | UNITIL Corporation | USD 55.58 | ▲ 0.45% |
| IDA | IDACORP, Inc. | USD 148.57 | ▼ 0.11% |
| POM | POMDOCTOR LIMITED | USD 0.71 | ▼ 11.35% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 09:44 UTC. This page is informational and not investment advice.